title: Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.
abstract: Our objective was to investigate whether cyclooxygenase-2 (COX-2) expression can predict the patient's response to chemoradiotherapy (CRT) and ensuing prognosis in esophageal squamous cell carcinoma (ESCC). The clinicopathological and follow-up data of 112 patients with ESCC who underwent CRT from January 2001 to June 2006 were analyzed retrospectively. The immunohistochemical expression level of COX-2 was examined for all biopsy specimens of primary tumors, and the correlation of COX-2 expression with the patient's response to CRT and prognosis was examined. COX-2 positive immunostaining was detected in 111 (99.1%) of the patients, including overexpression in 54 (48.2%) patients and low expression in 58 (51.8%) of the patients. The response of tumors with a low level expression of COX-2 (70.7%, 41/58) was significantly higher than that of tumors with COX-2 overexpression (42.6%, 23/54; P = 0.003). Patients with a low level of COX-2 expression had a higher downstaged rate than those with a high level of COX-2 expression (9/13 vs 2/8), but the difference was not statistically significant (P = 0.08). In the definitive CRT group (91 cases), COX-2 overexpression was significantly associated with poor 3-year overall survival (P = 0.028). Multivariate analysis showed that only metastatic stage (nonregional node metastasis) was an independent prognosis factor. The assessment of COX-2 status may provide additional information to identify ESCC patients with poor chances of response to CRT and potential candidates for more individualized treatment.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Sun-Yat-Sen University, Guangzhou, China.
authors.forename: W-Z
authors.initials: WZ
authors.lastname: Huang
authors.forename: J-H
authors.initials: JH
authors.lastname: Fu
authors.forename: D-K
authors.initials: DK
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.forename: M-Z
authors.initials: MZ
authors.lastname: Liu
authors.forename: H
authors.initials: H
authors.lastname: Yang
authors.forename: Y-F
authors.initials: YF
authors.lastname: Feng
authors.forename: B
authors.initials: B
authors.lastname: Zheng
authors.forename: G
authors.initials: G
authors.lastname: Wang
authors.forename: K-J
authors.initials: KJ
authors.lastname: Luo
authors.forename: J
authors.initials: J
authors.lastname: Wen
authors.forename: T-H
authors.initials: TH
authors.lastname: Rong
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000401:mortality* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000201:enzymology* / Q000401:mortality* / Q000628:therapy; D016629:Esophagectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D051546:Cyclooxygenase 2